Award
National Cancer Institute 5P50CA265826-05
Project 2
Recipient
Dana-Farber Cancer Institute, Boston, MA, United States
Award Amount
$438,838.00
Ceiling
$438,838.00
Awarded
July 23, 2026
Identifier
5P50CA265826-05
This award funds research on SMARCA4-mutant non-small cell lung cancer (NSCLC), aiming to characterize replication stress and immune activation, evaluate therapy sensitivity, and assess ATR inhibition combined with immunotherapy in preclinical models.
Description
Research on targeted therapies for SMARCA4-mutant NSCLC, focusing on replication stress and immunotherapy combinations. The project involves preclinical models and potential clinical trial development.